Hirva Mamdani, MD | Authors


Adjuvant Durvalumab Strategy in Locally Advanced Esophageal GEJ Adenocarcinoma

January 24, 2020

Hirva Mamdani, MD, explains the rationale for conducting a safety and efficacy study of durvalumab in patients following multimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma. Mamdani presented the 2-year follow-up data from this Big Ten Research Consortium study at the 2020 American Society of Oncology Gastrointestinal Cancers Symposium.